IndraLab
Statements
sparser
"The proteasome has both ubiquitin ligases and DUBs that associate with it (Crosas et al., 2006) , and several DUB-ligase pairs interact directly, including BRCC36-BRCA1, BAP1-BRCA1, USP4-Ro52, USP7-MDM2, USP8-GRAIL, USP20-pVHL, USP33-pVHL and USP44-APC (Kee and Huibregtse, 2007; Marfany and Denuc, 2008; Ventii and Wilkinson, 2008) ."
sparser
"Several studies and clinical trials [ xref ], have shown that PARP inhibitors influence cancers in which mutations in BRCA1 or BRCA2 are observed, which led us to assume that the cancerous growth-inhibiting interaction of BAP1 with BRCA1 may already be perturbed in this case, and that PARP inhibitors may actually be blocking the novel interaction of BAP1 with PARP3 which enhances cancer growth."
reach
"Myotubularin related protein 3 (MTMR3) induces the expression of p27; BRCA1 associated protein-1 (BAP1) interacts with BRCA1 and suppresses cancer cell growth; sphingosine-1-phosphate lyase 1 (SGPL1) may play a role in cancer-surveillance pathways; aryl-hydrocarbon receptor repressor (AHRR) is an angiogenic factor; and sialidase 1 (lysosomal sialidase) (NEU1) inhibits tumor metastasis by decreasing integrin beta4 signaling and down-regulating MMP-7."
sparser
"Several lines of evidences indicate that PARP inhibitor administration might be an effective treatment in presence of BAP1 and/or RAD21 alterations since both BAP1 and RAD21 are involved in the DNA repair pathway, BAP1 interacts with BRCA1 and BRCA1-mediated DNA repair pathway alterations enhance the sensitivity to PARP inhibitor administration."
sparser
"Because of the involvement of RAD21 in the DNA repair pathway, the interaction of BAP1 with BRCA1 and the enhanced sensitivity to PARP inhibitor administration in presence of alterations in the BRCA1-mediated DNA repair pathway, it was decided first to treat the patient with FOLFIRI every 2 weeks [irinotecan 180 mg/m 2 , folinic acid 400 mg/m 2 , 5-fluorouracil (5-FU) 400 mg/m 2 intravenous infusion bolus, then 5-FU 2400 mg/m 2 intravenous infusion over 46 h] and then to start a PARP inhibitor."
reach
"Several lines of evidences indicate that PARP inhibitor administration might be an effective treatment in presence of BAP1 and/or RAD21 alterations since both BAP1 and RAD21 are involved in the DNA repair pathway, BAP1 interacts with BRCA1 and BRCA1 mediated DNA repair pathway alterations enhance the sensitivity to PARP inhibitor administration."
reach
"Although the molecular genetics of cutaneous melanomas have been investigated in numerous studies [XREF_BIBR, XREF_BIBR, XREF_BIBR], the genetic events that lead to the development of CBN, MABN or ACBN are poorly understood and are limited to a few genes [XREF_BIBR, XREF_BIBR, XREF_BIBR - XREF_BIBR], including BAP1 (BRCA1 binding protein 1), an oncogenic deubiquitinase, which has been found to be mutated in metastatic uveal melanomas and MABNs [XREF_BIBR]."
sparser
"BAP1 belongs to a subfamily member of deubiquitinating enzymes and is a novel ubiquitin carboxy-terminal hydrolase.[ xref , xref ]BAP1 can bind to BRCA1 in the nucleus and increase BRCA1 tumor suppressor activity.[ xref ]It was reported that BAP1-related ceRNA (NEAT1/miR-10a-5p/SERPINE1) promotes kidney cancer cell proliferation and migration.[ xref ]SETD2 is a histone H3 lysine 36 (H3K36) trimethyltransferase and is one of the frequently mutated genes in ccRCC.[ xref ]SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.[ xref ]"
reach
"Due to the interaction between BAP 1 and BRCA1, studies are now investigating for the potential to treat with PARP inhibitors, with The Mesothelioma Stratified Therapy (MiST) nonrandomized phase II trial showing that PARP inhibition with rucaparib in refractory malignant mesothelioma of any type resulted in 58% disease control at 12 weeks, 23% at 24 weeks, and was well tolerated [88•]."